Fresh Evidence presented at the Chicago Symposium
October 30, 2005 – Chicago. New results, based on studies of an experimental model designed to investigate consumption of soy-derived products as a natural alternative to hormone replacement therapy in post-menopausal breast cancer women, were presented today at the 6th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease.
Fruit of the now consolidated collaboration between Indena researchers and scientists from the Policlinico Gemelli Hospital in Rome, these results provide evidence that consumption of Soyselect® (a standardized soy extract containing isoflavones and saponins), does not stimulate the growth of breast cancer tumors in the experimental model used (xenograft MCF-7).
Daniela Gallo, a scientist with the Gynaecology Oncology Department in the world-famous Roman hospital, explained that “Soy-derived products may induce a moderate estrogenic effect on estrogen dependent cells, without increasing cellular proliferation and tumor growth”.
The study also highlighted a decrease in the expression of other genes involved in tumor progression and angiogenesis, such as Thrombospondin 1 and Transforming Growth Factor β2.
Though positive these experimental results have yet to be confirmed by a full clinical analysis.
The role of Soyselect® to alleviate menopause and post-menopause symptoms is well known as it has been extensively studied by Indena with pharmacokinetic, toxicological and clinical testing to ensure its safety and efficacy.
Commenting on the results of the study, Paolo Morazzoni, Indena Scientific Board Director, was delighted to observe that “breast cancer patients, clearly a group of women most in need of natural alternatives, were today being offered further safeguards for the prospective consumption of Soyselect®”.
For further information please visit www.soyselect.info.
Indena is the world's leading company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health food and cosmetics industries. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. Backed up by over 80 years of botanical experience, the phyto-chemical research is carried out in Indena's own Settala Research Center, near Milan. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. The company, with around 800 employees, including 10% dedicated to full-time research, manages cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The Company's experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMEA, and ESCOP, and work with all the main pharmacopoeias.
Further Information on Indena:
Indena Research site